Amikacin Therapy of Urinary tract infections.
The efficacy and safety of amikacin in treatment of patients with urinary tract infections were evaluated. Underlying urologic disease was prevalent in the population studied. Amikacin was administered to 50 patients in a dosage of 7.5 mg/kg twice daily. In a subsequent study, amikacin was compared with gentamicin in the treatment of 63 patients; amikacin was administered in a dose of 150 or 200 mg every hr, and gentamicin was administered in doses of 60-80 mg every 8 hr. In the initial study, amikacin produced a bacteriologic cure rate of 86%. In the comparative study, cure rates for gentamicin and amikacin were 85% and 81% respectively. No significant renal toxicity or audiometric changes were attributed to amikacin.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000583:Amikacin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004756:Enterobacteriaceae Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D005839:Gentamicins; D007612:Kanamycin; D000583:Amikacin